Global Natural Killer Cell Therapy Market 2022 - Snapshot
The global natural killer cell therapy market is projected to expand at a CAGR of ~36.8 percent across the forecast period of 2022 - 2028, according to the latest edition of the Global Natural Killer Cell Therapy Market Report.
This industry report offers market estimates of the global market, followed by a detailed analysis of the therapy type, indication, and region. The global market data on natural killer cell therapy can be segmented by therapy type: CAR-NK cell therapy (modified), NK cell engager, NK cell therapy (unmodified). Natural killer cell therapy market is further segmented by indication: acute myeloid leukemia (AML), hepatocellular carcinoma (HCC), peripheral T-cell lymphoma (PTCL), relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). Based on region, the natural killer cell therapy market is segmented into: Asia Pacific, Europe, North America.
The global natural killer cell therapy market is highly competitive. Top players covered in Global Natural Killer Cell Therapy Market Study are Acepodia Inc., Affimed N.V., Celularity Inc., Century Therapeutics Inc., Cytovac A/S, Dragonfly Therapeutics Inc., Fate Therapeutics Inc., Gamida-Cell Ltd., GC Biopharma Corp., Glycostem Therapeutics B.V., iCell Gene Therapeutics LLC, ImmunityBio Inc., Innate Pharma S.A., Nkarta Inc., Sanofi S.A., Senti Biosciences Inc., Shoreline Biosciences Inc., Takeda Pharmaceutical Company Limited, VaxCell Biotherapeutics Co. Ltd.
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook